Find a Doctor

Jessica Louise Boklan, MD

Director, Clinical Oncology Research; Director, Early Drug Development Program; Co-Director, Leukemia, Lymphoma, Histiocytosis Program
, Hematology & Oncology

Office: Phoenix Childrens Medical Group - Hematology / Oncology
Address: 1919 E Thomas Rd, Phoenix, AZ 85016-7710
Phone: (602) 933-0920
Fax: (602) 933-0276
Professional Affiliations: American Academy of Pediatrics; American Association for Cancer Research; American Society of Hematology; Arizona Children’s Therapeutic and Investigational Oncology Network; Pediatric Oncology Experimental Therapeutics Investigators’ Consortium; Pediatric Blood and Cancer; Children’s Oncology Group; American Society of Clinical Oncology; Therapeutic Advances in Childhood Leukemia & Lymphoma (TACL)
Academic Affiliations: Assistant Professor of Clinical Pediatrics, University of Arizona College of Medicine, Tucson, AZ; Associate Member, Arizona Cancer Center
Degree/Certifications: MD
Board Certifications: Pediatric Hematology-Oncology
Medical School/Education: New York University School of Medicine, New York, NY
Residency: Children's Hospital of Philadelphia, Philadelphia, PA
Fellowship: (Pediatric Hematology/Oncology) Memorial Sloan-Kettering Cancer Center, New York, NY
Dr. Boklan has been a faculty member at Phoenix Children’s Hospital since 2001. Her clinical focus is on leukemia, with an emphasis on the various types of myeloid leukemias. She is Co-Director of the hospital’s Leukemia Program. Dr. Boklan also specializes in care for children with bone marrow failure syndromes including aplastic anemia. In addition to her areas of clinical focus, Dr. Boklan is Director of Clinical Oncology Research where she supervises all oncology clinical trials carried out at PCH. Her specific interest is in early drug development. As Director of the Early Drug Development Program, she concentrates on evaluating new drugs for patients who do not respond to currently available pediatric cancer treatments.

Dr. Boklan grew up in New York. She obtained her BA in Biochemical Sciences with honors from Harvard University. As an undergraduate, she spent two years in a laboratory, studying the molecular underpinnings of cancer development. She was awarded the Eliot House thesis prize for her work. Dr. Boklan received her MD from New York University School of Medicine where she was elected to the Alpha Omega Alpha Honor Society as well as earning numerous other academic achievement awards. Dr. Boklan then completed her residency in pediatrics at Children’s Hospital of Philadelphia followed by her pediatric hematology-oncology fellowship at Memorial Sloan-Kettering Cancer Center (MSKCC) and New York Hospital. Dr. Boklan’s fellowship research involved stem cell gene therapy and looking at new approaches for molecularly-targeted cancer treatment. Following completion of her fellowship, Dr. Boklan spent an additional year continuing her research at MSKCC as the Charles H. Revson Fellow in Biomedical Research and Charles A. Dana Postdoctoral Research Fellow.

Dr. Boklan subsequently moved across the country to Phoenix, where she joined the faculty of Phoenix Children’s Hospital. Since her arrival, she has built the oncology clinical research program into one with international recognition and membership in multiple prestigious consortia alongside some of the world’s major pediatric cancer centers. She currently serves as the PCH Principal Investigator for the Children’s Oncology Group (COG), the Pediatric Oncology Experimental Therapeutics Investigators’ Consortium (POETIC) and Therapeutic Advances in Childhood Leukemia and Lymphoma (TACL). Dr. Boklan works with her clinical partners in other academic centers as well as pharmaceutical companies to develop studies with the most promising agents available and bring them to pediatric patients. She also works closely with her laboratory collaborators to investigate new targeted agents and determine which would be best to move forward into clinical trials.

When Dr. Boklan is not running around caring for patients or supervising trials, she can be found in the hallways playing with her furry associates. Dr. Boklan also serves as the Medical Advisor for the PCH’s Animal Assisted Therapy Program.
Research/Special Interests: Leukemia, Bone Marrow Failure, New Cancer Drug Development
Publications: Boklan J. Little Patients, Losing Patience: Pediatric Cancer Drug Development. Commentary. Molecular Cancer Therapeutics. August 2006, Vol 5(8); 1905-1908.

Gao S, Mobley A, Miller C, Boklan J, Chandra J. Potentiation of reactive oxygen species is a marker for synergistic cytotoxicity of MS-275 and 5-azacytidine in leukemic cells. Leukemia Res. May 2008, Vol 32; 771-780.

Trippett TM, Herzog,C, Whitlock JA, Wolff J, Kuttesch J, Bagatell R, Hunger S, Boklan J, Smith AA, Arceci RJ, Katzenstein HM, Harbison C, Zhou X, Lu H, Langer C, Weber M, Gore L. Phase I and Pharmacokinetic Study of Cetuximab and Irinotecan in Children with Refractory Solid Tumors: A Study of the Pediatric Oncology Experimental Therapeutic Investigators’ Consortium. J Clin Oncol. Oct 2009, Vol 27; 5102-5108.

Hoeksema K, Jayanthan A, Cooper T, Gore L, Trippett T, Boklan J, Arceci R, Narendran A. Systemic in-vitro evaluation of the NCI/NIH Developmental Therapeutics Program Approved Oncology Drug Set for the identification of a candidate drug repertoire for MLL-rearranged leukemia. OncoTargets and Therapy. 2011, Vol 4; 149-168.

Elmoneim AA, Gore L, Ricklis RM, Boklan J, Cooper T, Narendran A, Rolla K, Scott T, Arceci RJ. Phase I dose-escalation trial of clofarabine followed by escalating doses of fractionated cyclophosphamide in children with relapsed or refractory acute